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Skin and Blood of Psoriasis Patients
Marcel B.M. Teunissen1,7, J. Marius Munneke2,7, Jochem H. Bernink3, Phyllis I. Spuls1, Pieter C.M. Res1,
Anje te Velde3, Stanley Cheuk4, Marijke W.D. Brouwer1, Stef P. Menting1, Liv Eidsmo4, Hergen Spits5,
Mette D. Hazenberg2 and Jenny Mjo¨sberg6
Innate lymphoid cells (ILCs) are increasingly appreciated as important regulators of tissue homeostasis and
inflammation. However, their role in human skin remains obscure. We found that healthy peripheral blood
CD117þ ILC3, lacking the natural cytotoxicity receptor (NCR) NKp44 (NCR ILC3), CD117NCRCRTH2
CD161þ ILC1, and CRTH2þ ILC2, express the skin-homing receptor cutaneous lymphocyte antigen (CLA). NCRþ
ILC3 were scarce in peripheral blood. Consistently, we identified in normal skin ILC2 and NCR ILC3, a small
proportion of CD161þ ILC1, and hardly any NCRþ ILC3, whereas NCRþ ILC3 were present in cultured dermal
explants. The skin ILC2 and NCRþ ILC3 subsets produced IL-13 and IL-22, respectively, upon cytokine stimulation.
Remarkably, dermal NCR ILC3 converted to NCRþ ILC3 upon culture in IL-1b plus IL-23, cytokines known to be
involved in psoriatic inflammation. In line with this observation, significantly increased proportions of NCRþ
ILC3 were present in lesional skin and peripheral blood of psoriasis patients as compared with skin and blood of
healthy individuals, respectively, whereas the proportions of ILC2 and CD161þ ILC1 remained unchanged. NCRþ
ILC3 from skin and blood of psoriasis patients produced IL-22, which is regarded as a key driver of epidermal
thickening, suggesting that NCRþ ILC3 may participate in psoriasis pathology.
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INTRODUCTION
Innate lymphoid cells (ILCs) is the collective term for a group
of hematopoietic cells with a lymphoid morphology, all of
which lack rearranged antigen-specific receptors such as those
expressed by T and B cells (Spits and Di Santo, 2011; Spits and
Cupedo, 2012). ILCs are defined as lineage-negative (Lin )
cells with a lymphoid morphology that express the a-chain of
the IL-7 receptor (CD127). ILCs are effector cells that perform
their function via the release of cytokines and have been
described to be involved in protective responses against
microorganisms, in lymphoid tissue formation, in tissue
remodeling after damage, and in the homeostasis of tissue
stromal cells (Spits and Di Santo, 2011; Spits and Cupedo,
2012). The prototypic members of this family are the Natural
killer (NK) cells that provide protection against viruses and
tumors. Over the last decade, other members of the ILC family
have been identified that are developmentally related to NK
cells, as they all depend on the transcription factor Id2 and the
common g-chain of the IL-2 receptor (IL2Rgc). ILC subsets
have been classified into three groups on the basis of
transcription factor expression and cytokine production
profile (Spits et al., 2013). Group 3 ILCs (ILC3), which may
express natural cytotoxicity receptors (NCR) including NKp44,
rely on the transcription factor RORgt, respond to IL-1b and IL-
23, and produce IL-17 and/or IL-22. These cells are involved
in tissue remodeling and tissue protection in both mice and
humans. ILC3 include the lymphoid tissue inducer (LTi) cells
that are crucial for formation of lymph nodes during fetal
development (Cupedo et al., 2009). Another subset distinct
from ILC3, ILC2, was recently described in the context of lung
tissue protection and helminth parasite expulsion in the gut
(Moro et al., 2010; Neill et al., 2010; Price et al., 2010;
Monticelli et al., 2011). In humans, these cells express CRTH2
(Mjo¨sberg et al., 2011), lack NKp44, produce type 2 cytokines
such as IL-5 and IL-13 (Mjo¨sberg et al., 2011, 2012), and are
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GATA-3 dependent (Mjo¨sberg et al., 2012). More recently, we
described a population of CD117NKp44 ILC that are
distinct from NK cells and dedicated to the production of
IFN-g, and hence termed ILC1 (Bernink et al., 2013). These
cells express the transcription factor T-bet, respond to IL-12
plus IL-18 by production of IFN-g, and are enriched in the
inflamed ileum mucosa of patients with Crohn’s disease
(Bernink et al., 2013).
As ILCs are crucial in mucosal defense, it is reasonable to
assume that they are also involved in immune defense and
tissue repair of the skin, which is one of the body’s largest
physical and immunological barriers. Indeed, a previous
report demonstrated the presence of NKp44þ ILCs in inflamed
human skin (Cella et al., 2009). More recently, RORgtþ ILC3
have been observed in Aldara-induced skin inflammation
(Pantelyushin et al., 2012) that in some, but not all, aspects
resembles psoriasis (Nestle et al., 2009), one of the most
common inflammatory disorders of the skin. Previous studies
have ascribed IL-23, which induces IL-17 and IL-22 pro-
duction from T-helper cells, as the essential cytokine for
driving skin inflammation (Pantelyushin et al., 2012).
However, recent studies demonstrate that Aldara-induced
psoriasiform skin inflammation occurs to the same extent in
Rag1/2 / mice lacking T and NK T cells (Hedrick et al.,
2009; Pantelyushin et al., 2012), but not in Rag2–/–Il2rgc /
mice that in addition lack ILC and conventional NK cells.
These experimental studies suggest that skin-invading RORgþ
ILC3 can induce a pathology with some resemblance to
psoriasis (Pantelyushin et al., 2012).
Here we examined the ILC populations that are the most
dominant in skin of healthy donors, CD117CRTH2NCR
CD161þ ILC1, CRTH2þ ILC2, and NCR ILC3. Few NCRþ
ILC3 were present in normal skin, whereas these NCRþ ILC3
were present in cultured dermal explants. Skin ILC2 and
NCRþ ILC3 were functional as they responded to cytokine
stimulation by secreting IL-13 and IL-22, respectively. NCR
ILC3 cultured in vitro with IL-1b plus IL-23 converted to
NCRþ ILC3 cells. Strikingly increased proportions of NCRþ
ILC3 were present in human psoriatic skin lesions as com-
pared with normal skin. The increase in NCRþ ILC3 in the
skin of psoriasis patients was mirrored by similar increases in
peripheral blood NCRþ ILC3 of psoriasis patients as com-
pared with healthy individuals. Both blood and skin NCRþ
ILC3 produced IL-22, but very little IL-17. These data suggest
that NCRþ ILC3, by providing a source of IL-22, may
participate in psoriasis pathology.
RESULTS
Composition of human ILC subsets in normal human adult skin
Recently, we and others identified several ILC populations in
humans that can be classified in three groups on the basis of
the expression of c-Kit (CD117), NKp44, and CRTH2 (Spits
et al., 2013). As ILCs are involved in tissue immunity,
remodeling, and epithelial barrier maintenance in the lung
and gut (Sonnenberg and Artis, 2012; Spits and Cupedo, 2012;
Walker et al., 2013), we hypothesized that ILCs would also be
involved in skin immunity and homeostasis. With this
background, we set out to determine the composition of
ILCs present in adult normal human skin. Freshly prepared,
single-cell suspensions from dermis of healthy individuals
contained a discrete population of CD45þ cells lacking Lin
markers for T cells (CD3, TCR), B cells (CD19), NK cells
(CD94), myeloid and plasmacytoid dendritic cells (CD1a,
CD11c, CD123, BDCA2), monocytes and macrophages
(CD14), mast cells (FceR1), and stem cells (CD34) (Figure 1a).
These CD45þLin cells with lymphoid morphology and high
expression of CD127 represented 1.3±0.3% of the CD45þ
dermal lymphocytes (Figure 1a and b). Approximately 25%
(24.2±9.9%) of these cells expressed CRTH2 (Figure 1a
and b), a marker for human ILC2 (Mjo¨sberg et al., 2011).
Interestingly, the IL-22-producing NCRþ ILC3 population,
which we previously described in tonsil and gut mucosa
(Crellin et al., 2010; Bernink et al., 2013), could hardly be
found in freshly prepared dermal-cell suspensions (1.3±0.6%
of CD45þLinCD127þ ILC, Figure 1a and b), which is
similar to the very low proportions of NCRþ ILC3 in peripheral
blood (Figure 2). Importantly, the absence of NCRþ ILC3 in
these freshly prepared dermal-cell suspensions could not be
explained by enzymatic cleavage of NKp44 as experiments
showed that the enzymes used (dispase II and collagenase D)
did not considerably affect expression of critical ILC
markers such as CD127, CD117, CRTH2, or NKp44
(Supplementary Figure S1 online). Of note, we also observed
a prominent population of CD117CRTH2NKp44 ILCs in
both freshly isolated dermal-cell suspensions (39.8±14.4%)
and dermal crawl-out cultures (24.8±11.0%) (Figure 1).
Phenotypically, this population resembles the ILC1 that we
recently described to be accumulated in Crohn’s disease ileum
(Bernink et al., 2013). However, only a minority of this skin
population expressed the pan-ILC marker CD161 (Figure 1),
indicating that the ILC3-derived ILC1 that we identified (Bernink
et al., 2013) are very rare in the normal skin, comparable to
our findings in non-inflamed intestine (Bernink et al., 2013).
Hence, this prevented us from performing functional studies of
these cells.
Peripheral blood ILCs express the skin-homing marker CLA
A likely source of skin ILCs would be peripheral blood, in
which, CD117CRTH2NCR ILC1, CRTH2þ ILC2, and
NCR ILC3 are present (Mjo¨sberg et al., 2011; Bernink et al.,
2013). To test our hypothesis, we examined the expression of
the skin-homing markers cutaneous lymphocyte antigen (CLA)
and CCR10 on peripheral blood ILCs (Figure 2). Interestingly,
both ILC2 and NCR ILC3 expressed the skin-homing
marker CLA, whereas few cells expressed CCR10, which
was restricted to the CLAþ ILC population (Figure 2). Strik-
ingly, the proportion of NCRþ ILC3 was very low in
peripheral blood from healthy donors (Figure 2), which
correlates well with the very low percentages of NCRþ ILC3
in freshly isolated normal skin (Figure 1).
Function of dermal ILC2
CRTH2þ ILC2 were also present in so-called crawl-out
dermal-cell suspensions (Figure 1b), representing cells that
had migrated out of cultured dermal explants. Both freshly
isolated and crawl-out CRTH2þ ILC2 showed high expression
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of CD161 and a variable expression of CD117 (Figure 1),
concurrent with the phenotype of ILC2 that we previously
identified in human peripheral blood and nasal polyps
(Mjo¨sberg et al., 2011, 2012). Freshly prepared and
crawl-out flow cytometry–sorted dermal CRTH2þ ILC2
responded to IL-33 plus thymic stromal lymphopoietin (TSLP)
stimulation with secretion of IL-13 (Figure 3a), confirming
their similarity to the previously described human ILC2
(Mjo¨sberg et al., 2011, 2012). In addition, ILC2 cell lines
could be established, which maintained their expression of
CRTH2, CD127, and CD117 (Figure 3b) and lacked markers
for T and NK cells (CD3 and CD94, data not shown).
Furthermore, these cells expressed CD25 (Figure 3b), a
previously described marker for human ILC2 (Monticelli
et al., 2011). Upon stimulation with phorbol 12-myristate
13-acetate (PMA) plus ionomycin, these skin ILC2 cell lines
produced IL-13 (Figure 3b). Furthermore, ILC2 cell lines
responded to TSLP with increased production of IL-13 and
IL-5, especially in the combination with IL-25, which together
exerted a synergistic effect on inducing IL-13 production
(Figure 3c and d). Noteworthy, addition of IL-33 to this mix
did not further enhance IL-13 production, and TSLP plus IL-33
did not synergistically enhance IL-13 production as compared
with TSLP or IL-33 alone (Figure 3c and d). Hence, in contrast
to previously published data on ILC2 in polyps and blood
where IL-33 and TSLP synergistically enhance type 2 cytokine
production (Mjo¨sberg et al., 2012), ILC2 in the skin are mainly
regulated by TSLP and IL-25 and to a lesser extent by IL-33. In
contrast to blood and polyp ILC2 (Mjo¨sberg et al., 2012), skin
ILC2 cell lines did not produce significant levels of IL-4, IL-9,
or GM-CSF (data not shown). Of note, a minority of the
cultured ILC2 co-expressed IFN-g and IL-22, and to a lesser
extent IL-17 (Figure 3b), in accordance with our previous
studies of blood and polyp ILC2 (Mjo¨sberg et al., 2011, 2012).
However, this was only seen with PMA/ionomycin stimulation
but not with ILC2-specific stimulations such as IL-25, IL-33,
and TSLP (data not shown). Hence, ILC2 seem to have
the capacity to produce some IL-22 and IFN-g; however, the
physiological triggers and importance of this production
remains unknown.
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Figure 1. Innate lymphoid cells in normal human skin. (a) Flow cytometry analysis of Lin–CD127hi ILC within the CD45þ lymphocyte population in
freshly prepared cell suspensions (upper panel) and crawl-out cells from dermal explant cultures (lower panel). Numbers in gates (outlined areas) and quadrants
indicate percent cells in each throughout. Histograms depict CD161 expression by CRTH2þ ILC2 (black line), CD117þNKp44– cells (dashed line),
CD117þNKp44þ ILC3 (dotted line), and CD117–NKp44– cells (light gray shading). The lineage ‘cocktail’ included antibodies to CD1a, CD3, CD4, CD11c,
CD14, CD19, CD34, CD123, TCRab, TCRgd, BDCA2, FceR1, and CD94. (b) ILC subpopulation distribution in normal human skin is dependent on the method
used for sample preparation. Data are depicted as the mean percentage±SD and are representative of 10 independent experiments with one donor each.
ILC, innate lymphoid cell; Lin, lineage.
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Capacity of skin NCR ILC3 to convert into NCRþ ILC3
Despite the very low numbers of NCRþ ILC3 in cell suspen-
sions prepared from freshly isolated skin, we consistently
found a prominent CRTH2 ILC population (26.5±8.6%)
expressing CD161 and NKp44 (NCRþ ILC3) (Figure 1a and b)
in the crawl-out CD45þLin ILCs from dermal explant
cultures. Previously, we have documented that, in the tonsil,
NKp44 identifies a population of ILC3 that responds to IL-1b
plus IL-23 with production of IL-22 (Crellin et al., 2010;
Bernink et al., 2013). In agreement with this, isolated crawl-
out NCRþ ILC3 from dermal explant cultures expressed
RORgt (Figure 3e) and secreted IL-22 when they were exposed
to IL-1b plus IL-23 for 4 days (Figure 3f), suggesting that NCRþ
ILC3 provide a source of IL-22 in skin.
We recently showed that NCR ILC3 isolated from human
tonsils and fetal intestine differentiate to NCRþ ILC3 under the
influence of IL-1b plus IL-23 (Bernink et al., 2013). Hence, we
reasoned that the NCRþ ILC3 population found in crawl-out
cultures might have arisen during the 3-day culture of the
explant, deriving from a skin-resident NCR ILC3 population.
Indeed, such a NCR ILC3 population, expressing CD161,
could be found in both freshly prepared dermal-cell suspen-
sions and crawl-outs derived from normal skin (Figure 1).
When cultured in IL-1b plus IL-23, these cells readily
converted into NCRþ ILC3 (Figure 4a). The majority of these
cells expressed CD161 and CD56 (Figure 4b). Of note, NCR
ILC3 did not give rise to CRTH2þ ILC2 upon culture with
either IL-1b plus IL-23 or TSLP plus IL-33 (Figure 4a).
In summary, in addition to differentiated ILC2, normal skin
harbors a NCR ILC3 population, which can convert into
NCRþ ILC3 with the capacity to produce IL-22.
NCRþ ILC3 accumulate in skin lesions and peripheral blood of
patients with psoriasis
Although the contribution of T cells to the pathogenesis of
psoriasis is well established (Nestle et al., 2009; Res et al.,
2010), it is becoming increasingly clear that the innate
immune system also participates in the initiation and/or
maintenance of psoriatic inflammation (Bos et al., 2005).
We set out to examine the presence and frequency of ILCs
in freshly prepared lesional skin of psoriasis patients as
compared with normal skin of healthy individuals. To this
end, we collected blood, as well as biopsies from active
lesions of psoriasis patients to be compared with normal skin
and blood from healthy individuals. Strikingly, flow cytometric
phenotypical analysis of the ILC populations revealed that
psoriatic skin contained significantly higher proportions of
total LinCD127þ ILCs (Figure 5b). In addition, significantly
elevated frequencies of NCRþ ILC3 were seen in both skin
and blood from psoriasis patients as compared with normal
skin and blood from healthy individuals (Figure 5a–d).
Noteworthy, the frequency of NCRþ ILC3 in the skin
correlated with psoriasis severity (psoriasis area and severity
index scores; P¼0.042; Figure 5e).
By contrast, the frequencies of ILC2 were similar in normal
and psoriatic skin and blood (Figure 5a–d). Furthermore, we
did not find any evidence for alterations in the frequency of
CD161þ ILC1 in psoriatic as compared with healthy skin
(Figure 5b).
To assess the cytokine production from psoriasis-associated
NCRþ ILC3, we sorted and in vitro expanded these cells from
the blood and dermal crawl-out cultures of psoriasis patients.
Upon IL-1b/IL-23 plus PMA/ionomycin stimulation, blood and
skin NCRþ ILC3 produced IL-22, but few cells produced IL-17
(Figure 6a–e). A larger proportion of NCRþ ILC3 in the skin as
compared with the blood seemed to produce IL-22, both at
resting and IL-1b/IL-23 plus PMA/ionomycin-stimulated con-
ditions; however, due to the small number of observations, we
were not able to assess this with statistical certainty. Impor-
tantly, we could also show that IL-22 was secreted from
psoriasis blood–derived NCRþ ILC3 (Figure 6f), but not NK
cells or ILC2 (data not shown). IL-22 was secreted both
spontaneously and in response to IL-1b plus IL-23 stimulation,
which further increased the production of IL-22 (Figure 6f). No
secreted IL-17 was detected from these NCRþ ILC3.
Hence, our finding of increased numbers of NCRþ ILC3 in
lesional psoriatic skin and blood is likely to be clinically
relevant, as these cells potently produce IL-22, a cytokine
known to contribute to the epidermal thickening that is char-
acteristic for this inflammatory skin disease (Zheng et al., 2007).
DISCUSSION
In this study, we provide a detailed characterization of the
LinCD127þ ILC phenotypes found in the normal skin of
healthy humans. Furthermore, we show that all ILC popula-
tions found in the blood, including NCR ILC3 and CRTH2þ
ILC2, have the capacity to migrate to and populate the skin, as
part of these cells express CLA. Consistently, we identified in
healthy human skin ILC2 and NCR ILC3, but hardly any
CD161þ ILC1 or NCRþ ILC3, whereas NCRþ ILC3 were
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present in cultured dermal explants. The ILC2 and NCRþ ILC3
subsets in healthy human skin were functional as they
produced IL-13 and IL-22, respectively, upon cytokine stimu-
lation. The scarcity of CD161þ ILC1 prevented us from
performing functional studies of these cells. Extended char-
acterization of the skin CRTH2þ ILC2 revealed that they
could be expanded in vitro in high-dose IL-2 without loss of
phenotype or function as they maintained CD127, CRTH2,
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CD117, and CD25, lacked markers for T and NK cells (CD3
and CD94), and retained their capacity to produce IL-13
following in vitro culture. These data show that the skin ILC2
are a stable subset of cells that can be driven to proliferation
by high-dose IL-2, a finding consistent with a recent paper
describing mouse ILC2 (Roediger et al., 2013). Interestingly, in
contrast to blood and nasal polyp ILC2, which respond
vigorously to TSLP plus IL-33 (Mjo¨sberg et al., 2012), TSLP
plus IL-25 more potently triggered IL-13 production than the
combination TSLP plus IL-33. Recently, Kim et al. (2013)
published data from a mouse model of atopic dermatitis
demonstrating that cutaneous allergic inflammation is
critically dependent on TSLP-driven ILC2 responses.
However, ILC2 inflammation in the mouse skin occurred
independently of IL-25 and IL-33. In our study, we did not
address the role for ILC2 in atopic dermatitis; however, our
data on healthy human skin ILC2 clearly show that IL-25, and
to a lesser extent also IL-33, enhances the capacity of TSLP to
stimulate ILC2, findings that may have implications when
considering these pathways as targets in the treatment of
atopic dermatitis. The demonstration that CRTH2þ ILC2 are
present in normal human skin is in contrast with the data of
Kim et al. (2013) who showed that, although ILC2, identified
as Lin IL33RþCD25þ ILC, were present in healthy skin, they
lacked expression of CRTH2. The reason for this discrepancy
is unknown but may be attributed to the use of different cell
surface–identification markers and flow cytometric gating
strategies.
Importantly, we identified IL-1b plus IL-23-responsive IL-22-
producing NCRþ ILC3 in cell suspensions obtained from
dermal explant cultures derived from the skin of healthy
individuals. These cells were scarce in freshly isolated skin-
cell suspensions. This led us to hypothesize that these cells
were derived from NCR ILC3 that were present in both
freshly isolated dermal-cell suspensions as well as in dermal
crawl-out cultures. Indeed, in accordance with what we
previously observed in fetal intestine and tonsil (Bernink
et al., 2013), dermal NCR ILC3 cultured with IL-1b plus
IL-23 converted to NCRþ ILC3. This observation is intriguing
in the context of skin inflammation, as IL-1b and IL-23 are
upregulated in psoriatic lesions (Debets et al., 1997; Lee et al.,
2004; Piskin et al., 2006) and implicated in pathogenesis of
the disease (Zheng et al., 2007). Indeed, we found an
accumulation of IL-22-producing NCRþ ILC3 in freshly
isolated lesional skin and blood of psoriasis patients.
Paralleling our findings, it was recently reported that the
number of ILC3 is increased in 12-day-old crawl-out
cultures of psoriasis skin (Dyring-Andersen et al., 2014). This
study did not, however, assess the frequency of different ILC
populations in freshly isolated skin biopsies or blood of
psoriasis patients, which is likely to yield a more relevant
view of the in vivo ILC status of these patients. Furthermore,
during the review process of our manuscript, another study
demonstrated an accumulation of NCRþ ILC3 in psoriasis
(Villanova et al., 2014). This paper suggested NCRþ ILC3 as
sources of both IL-22 and IL-17 in psoriasis. However,
Villanova et al. (2014) did not demonstrate cytokine pro-
duction from pure ILC populations in the skin. Instead, they
examined CD45þCD3 cells, which, although enriched for
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Figure 5. Accumulation of NCRþ ILC3 in lesional skin and peripheral blood of psoriasis patients. (a) CD45þLin–CD127þ lymphocytes from healthy or
psoriatic lesional skin, representing the total ILC population, were subdivided into ILC2 and ILC3 on the basis of the mutually exclusive expression of CRTH2 and
NKp44. CD161þ ILCs that were negative for CRTH2, NKp44, and CD117 were regarded as ILC1. (b) Summary of the percentages of ILC subsets in human skin. In
the top row, ILC subsets are depicted as a percentage of CD45þ lymphocytes, while in the bottom row ILC subsets are depicted as a percentage of total
ILC. (c) Peripheral blood of healthy donors contains ILC2 and ILC1, but is devoid of NCRþ ILC3, whereas blood of psoriasis patients contains a clear population of
NCRþ ILC3. (d) A summary of the ILC subsets in blood depicted as percentage of CD45þ lymphocytes in the top row and depicted as a percentage of total
ILCs in the bottom row. (e) Correlation analysis of dermal NCRþ ILC3 frequency and psoriasis area and severity index (PASI) score. Sample numbers
may vary between groups. Horizontal lines indicate mean values±SD. **Po0.001. (e) Correlation analysis of blood and dermal NCRþ ILC3 frequency and
PASI score. ILC, innate lymphoid cell; Lin, lineage; NCR, natural cytotoxicity receptor.
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ILC, are not pure, and their results need to be interpreted with
caution. In a set of preliminary experiments, we confirmed
that CD45þCD3 cells isolated from the skin produce IL-17
following stimulation with PMA/ionomycin (Supplementary
Figure 2). This observation, together with our demonstration of
very low frequencies of IL-17þNCRþ ILC3, suggests that
IL-17 is produced by cells distinct from NCRþ ILC3 within the
CD45þCD3 population. Villanova et al. (2014) did not
assess which cytokines might drive the IL-17 or IL-22
production from NCRþ ILC3. Hence, our study further
extends these observations, as we demonstrated that the
IL-22 production, and to a lesser extent the IL-17 produc-
tion, was stimulated in purified blood and skin-derived NCRþ
ILC3 by the presence of IL-1b plus IL-23. In addition, we show
that culture of NCR ILC3 in IL-1b plus IL-23 increases
the frequency of NCRþ ILC3 in vitro, suggesting that
these cytokines not only stimulate cytokine production from
NCRþ ILC3 but may also contribute to the accumulation of
NCRþ ILC3 in psoriasis.
All together, our findings suggest that the elevated levels of
IL-1b and IL-23 found in the skin of psoriasis patients support
conversion of NCR ILC3 into NCRþ ILC3, the latter of
which constitutes a source of IL-22 in the skin, contributing to
the epidermal thickening that is characteristic for this inflam-
matory skin disease (Nakajima, 2012). Interestingly, elevated
numbers of NCRþ ILC3 were also present in peripheral blood
of psoriatic patients. This raises the possibility that NCR3þ
ILC3 are not only generated in the skin but also elsewhere and
then migrate to the skin. Of note, we did not find any evidence
for altered frequencies of CD161þ ILC1 in lesional skin of
psoriasis patients. As these cells are primarily induced by IL-12
(Bernink et al., 2013), this suggests that the effects of IL-23
dominate those of IL-12 in psoriatic skin lesions. It will be
highly interesting to see whether the numbers of NCRþ ILC3
in the peripheral blood and skin are modulated by therapy
targeting IL-23 in psoriasis.
IL-22 is not only produced by NCRþ ILC3 but also by T
cells in psoriasis. As T cells are more abundant, it is tempting
to assume that they represent the major source of IL-22.
However, the relatively lower frequency of NCRþ ILC3 as
compared with T cells does not diminish the importance of
NCRþ ILC3. A good example of this comes from studies of
ILC3 in the gut, where these cells are also rare. Mice lacking
IL-22-producing ILC3 show strikingly increased susceptibility
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Figure 6. NCRþ ILC3 from lesional skin and peripheral blood of psoriasis patients produce IL-22. (a) Flow cytometric cytokine analysis of cell lines
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with IL-2 (10 U ml 1), IL-23 plus IL-1b (both 50 ng ml 1) for 3 days, stimulated with PMA/ionomycin for 6 hours, and then stained for intracellular IL-22 and IL-17.
(b–e) Percentage of IL-22þ (b, c) and IL-17þ (d, e) blood- and skin-derived NCRþ ILC3 after stimulation with PMA/ionomycin after 3 days of pre-incubation with
either 10 U ml 1 IL-2 alone or in combination with IL-23 plus IL-1b (50 ng ml1). (f) IL-22 secretion of expanded blood-derived conventional NK cells and
NCRþ ILC3 after stimulation with either 10 U ml 1 IL-2 alone or in combination with IL-23 plus IL-1b (50 ng ml 1). Results were normalized to 8,000 cells per
200ml in a 96-well plate (f; mean and SEM). Data are representative of two (blood) or three (skin) psoriasis patients. Each patient sample was examined in
independent experiments. ILC, innate lymphoid cell; NCR, natural cytotoxicity receptor; PMA, phorbol 12-myristate 13-acetate.
MBM Teunissen et al.
Innate Lymphoid Cells in Human Psoriatic Skin
2358 Journal of Investigative Dermatology (2014), Volume 134
to the pathogen Citrobacter rodentium (Satoh-Takayama
et al., 2008). Furthermore, ILC3 and T-helper cells may
have complementary functions. Again, using the C.
rodentium infection model, it was shown that IL-22 was
induced from ILC3 and Th22 cells in sequential waves, each
crucial for host defense (Basu et al., 2012). Hence, although
numerically inferior, NCRþ ILC3 have a nonredundant
function in the gut, which may very well also be the case in
the skin.
In conclusion, we demonstrate that the ILC compartment in
normal human skin comprises functional ILC2 as well as
NCR ILC3, the latter of which can be converted to NCRþ
ILC3. In psoriatic skin lesions, however, these NCRþ ILC3 are
present in increased proportions, and as these NCRþ ILC3
provide a source of IL-22, they may, together with T cells,
participate in the pathogenesis of psoriasis.
MATERIALS AND METHODS
Skin and blood collection
The study protocols were reviewed and approved by the Medical
Ethical Committee of the Academic Medical Center, Amsterdam,
following the Declaration of Helsinki protocols. All material was
collected after patient’s written informed consent. Normal adult skin
was obtained as residual tissue after plastic surgery of the breast or
abdomen. Patients with active psoriasis vulgaris who visited the
Department of Dermatology at the Academic Medical Center in
Amsterdam donated 4 mm punch biopsies from an active lesion. All
patients refrained from any systemic therapy or phototherapy for at
least 4 weeks before participation and topical treatments were not
allowed 14 days before baseline. The mean psoriasis area and
severity index of the patients was 10.7±6.9. Some of the skin donors
(healthy and psoriatic) also donated peripheral blood that was
sampled via venipuncture.
Preparation of dermal and epidermal skin suspensions
Thin sheets of 0.3 mm thickness were shaved from residual
normal skin by an electrodermatome and were treated overnight
at 4 1C with 0.3% (wt/vol) dispase II (Roche, Almere, The Netherlands)
in PBS to enable the separation of dermis and epidermis. To get
fresh cell suspensions, the dermis was fragmented by scissors and
incubated in IMDM with 0.5% (wt/vol) collagenase D (Roche),
50 U ml 1 DNAse I (Sigma-Aldrich, St Louis, MO), and 0.5% (vol/
vol) FCS for 90 minutes at 37 1C. Alternatively, to allow spontaneous
migration of cells from the tissue, the dermis was cut into small pieces
of 2–4 cm squares and was cultured in IMDM with 10% FCS for
3 days. Skin biopsies from lesional skin of psoriasis patients were
treated subsequently with dispase and collagenase as described
above.
Flow cytometry analysis and sorting
The following antibodies to human proteins were used: FITC-
conjugated anti-CD1a (HI149), anti-CD3 (OKT3), anti-CD4 (RPA-T4),
anti-CD11c (3.9), anti-CD14 (HCD14), anti-CD16 (3G8), anti-CD19
(HIB19), anti-CD34 (581), anti-CD94 (DX22), anti-CD123 (6H6), anti-
FceR1a (AER-37), phycoerythrin (PE)-conjugated anti-CCR10 (6588-5)
anti-CD94 (HP-3D9), anti-CD161 (HP-3G10), anti-NKp44 (P44-8),
peridinin chlorophyll protein–cyanine 5.5 (PerCP-Cy5.5)-conjugated
anti-CD117 (104D2), Alexa Fluor 647–conjugated anti-NKp44
(P44-8), Pacific Blue-conjugated anti-CLA (HECA-452), allophyco-
cyanin-indotricarbocyanine (APC-Cy7)-conjugated anti-CD25 (BC96),
Brilliant Violet 421–conjugated anti-CD161 (HP-3G10), Alexa Fluor
700–conjugated anti-CD3 (UCHT1), anti-CD56 (HCD56; all from
BioLegend, San Diego, CA); FITC-conjugated anti-TCRab (IP26), anti-
TCRgd (B1), PE-conjugated anti-CD16 (3G8), Alexa Fluor 647–
conjugated anti-CRTH2 (CD294; BM16), APC-Cy7-conjugated anti-
CD45 (2D1), V500-conjugated anti-CD3 (UCHT1), and isotype-
matched control antibodies conjugated to Alexa Fluor 700 (MOPC-
21), PE, APC, or PE-Cy7 (X40; all from BD Biosciences, Mountain
View, CA); R Phycoerythrin-Cyanine 5.5 (PE-Cy5.5)-conjugated anti-
CD117 (104D2D1), R Phycoerythrin-Cyanine 7 (PE-Cy7)-conjugated
anti-CD127 (R34.34; both from Beckman Coulter, Woerden, The
Netherlands), and FITC-conjugated anti-BDCA2 (CD303; AC144;
Milenyi Biotec, Leiden, The Netherlands). Intracellular RORgt staining
was carried out using PE-conjugated anti-human RORgt (clone AFKJS-
9; eBioscience, San Diego, CA) and the Foxp3 permeablilization/
fixation kit according to the manufacturer’s instructions.
Generation of ILC lines
Purified Lin–CD127þCRTH2þ , Lin–CD127þCRTH2CD117þ
NKp44þ , and Lin–CD127þCRTH2CD117–NKp44– ILC popula-
tions were stimulated with 1mg ml 1 phytohemagglutinin (Oxoid,
Hampshire, UK), 25 Gy–irradiated allogeneic peripheral blood mono-
nuclear cells, 50 Gy–irradiated Epstein–Barr virus–transformed
JY human B cells, and 100 U ml 1 IL-2 (Novartis, Arnhem,
The Netherlands) in Yssel’s medium (prepared in-house (Yssel et al.,
1984)) supplemented with 1% (vol/vol) human AB serum. Culture
medium containing IL-2 was refreshed two times per week and cells
were re-sorted before further analysis.
Measurement of cytokine production
Purified fresh and expanded ILCs were cultured for 3–4 days at 2,000
cells per well in a round-bottomed 96-well plate in Yssel’s medium
supplemented with 1% (vol/vol) human serum in the presence or
absence of 10 U ml 1 IL-2 and stimulated with one of the following
cytokines or combinations thereof: 50 ng ml 1 TSLP, 50 ng ml 1
IL-25, or 50 ng ml 1 IL-33 (all from R&D systems, Abingdon, UK)
for Lin–CD127þCRTH2þ ILCs; 50 ng ml 1 IL-23 and 50 ng ml 1
IL-1b (both from R&D systems) for Lin–CD127þCRTH2CD117þ
NKp44þ ILCs and 50 ng ml 1 IL-12 and 50 ng ml 1 IL-18 (both from
R&D systems) for Lin–CD127þCRTH2CD117–NKp44– ILCs. IL-13,
IL-17, IL-22, and IFN-g were measured in culture supernatants by
enzyme-linked immunosorbent assays from R&D systems or Sanquin
(Amsterdam, The Netherlands). Alternatively, multiple cytokine detec-
tion (including IL-4, IL-9, and GM-CSF) in the supernatants was
performed using the MILLIPLEX MAP Human Cytokine/Chemokine
Panel (Merck Millipore, Billerica, MA) and the Bio-Rad Bioplex-200
analysis instrument (Bio-Rad, Hercules, CA), all according to the
manufacturer’s instructions. The Bioplex Manager 4.1 software was
used for data analysis. To detect intracellular cytokines, ILCs were
stimulated for 6 hours with 10 ngml 1 PMA (Sigma) and 500 nM
ionomycin (Merck) in the presence of GolgiPlug (BD Biosciences) for
the final 4 hours of culture. In some experiments, IL-23 and IL-1b
(50 ng ml 1) was added for the whole culture period. Cytofix/
Cytoperm kit (BD Biosciences) was used for permeabilization during
subsequent staining and washing steps. We used the following
antibodies: APC-conjugated anti-IL-13 (JES10-5A2) and APC-
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conjugated anti-IL-17 (BL168) from BioLegend; PE-conjugated anti-IL-
22 (142928) from R&D systems and PE-conjugated anti-IFN-g (B27)
from BD Biosciences. Data were acquired with LSR-Fortessa equip-
ment (BD Biosciences) and analyzed with FlowJo software (TreeStar,
Ashland, OR).
Statistical analysis
Statistical significance was determined with Student’s t-test and
Pearson correlation analysis using SPSS software.
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